Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Team effort
XenaLives: He hasn't bought any yet. They are for 6.26 and 7.06 Shows absolute confidence in the fundamentals, especially since they vest 1/9, 3/9, 5/9. Only a third of these vest this year.
§
Read these two pieces:
http://www.nature.com/news/2010/100407/full/464828a.html
http://www.anavex.com/files/Teruo11_1R_overview.pdf
"The major function of molecular chaperones at the ER is to
promote the proper folding of newly synthesized proteins. ER chaperones also regulate the
proteasomal protein degradation by transferring misfolded proteins to the ER-associated
degradation (ERAD) machinery[24]."
Did your heart start to flutter?
I get all giggly!
§
When? At eps 2.50 or right now, at eps -.08?
I'm trying to get at least 1MM sold up here. Carefully, of course!
§
Warrants? My give up!
TRUMPFORPRES: That's the reason Novalere did the deal, to capitalize on their investment. It's all figured into any future deal. Expect an exchange listing before any buyout offers.
Take care Dutchdaan. Best of luck!
§
True-dat! I averaged 48% on gutter buys from the re-balance, last week. Primed some short positions yesterday and executed on a few today...like that biotch AXON!
Just a hard swing by the bears to try and break the bubble.
AVXL tends to lead on the up & down. Still doing great against the indicators.
§
What microbe is this "vaccine" being developed with/against?
http://www.vaccines.gov/more_info/types/
Is it a DNA vaccine? They're going to give a 1-4 shot regimen and that supposedly will prevent the formation of AB aggregates? To whom, everybody?
AD is not an infectious disease. Anavex has the closest thing to a vaccine and already in human trials, yet they get slammed for being 'cautiously optimistic'.
AdvaxCpG sounds like a real pump-n-dump..."bankrolled by the US government" of course!
It's just another beta-amyloid auto-antibody.
Advaxumab...coming not-too-soon to a failed clinical trial near you!
§
Insiders did not buy. The filings were for private option shares from the merger. Squeezed-out Novalere shareholders have received their cash and are buying back INNV stock.
cl(d)ay trader explained:
http://investorshub.advfn.com/boards/AboutIRPs.aspx
http://investorshub.advfn.com/boards/IRP.aspx?userid=89929
Not making much these days
§
I wish I could. It lived in my form history for a while, but that was it. Don't know if I could re-put it into the majesty that it was, but that description was the jist.
I have read some quasi-confirmed statistics and I know a bunch of aging hipsters. They don't get AD. Some short term M4 stoner issues maybe, but not full-on dementia.
Leary passed blissfully after coming-to and saying a last, "Why not?" and "Yeah".
Outstanding Cbd!
I had a post worked up at one time relating/comparing the Sigma/muscarinic modulations to playing chords on a stringed instrument in "the body orchestra". With binding site affinities and direct vs allosteric modulation relating to muted/open strings, hammering on/off, harmonics, etc and the promise of the drug being able to bring the instrument back 'in tune'.
I ended up feeling like the comparison made it look like we were somehow trying to pick up an instrument, un-taught, and play these chords, or music, by pure chance. How utterly unlikely, I thought...so the piece perished.
In many ways it did seem to be a perfect comparative to what the science is trying to accomplish. And it's all mathematics in the end.
§
I had said:
"How about this. The Sun poster is titled exactly as the original CTAD 2015 abstract, but with the added 'Dose Dependent'. I surmised last year that the CTAD presentation appeared as though some slides were removed, leaving the one (#18 I think) for the only 12 week mark. Sunday's poster may be the full presentation of this 12 week data that they decided not to reveal until further analysis and 26 week results could assure that "there can be no doubt as to the cause-effect relationship of the 12-week efficacy data". That conforms to Occam's Razor.
Wednesday will be a full 26 week readout and AE report concluding that 'Results warrant advancing A2-73 into P2/3'. No 'CURE!'"
In-line with your thinking, Sun could be full 12 week update showing little change in ADCS-ADL and Cogstate, then more robust 26 week data on Wed.
I suspect some sort of 1-2 punch here...as some on the boards have expressed displeasure in not seeing so-far.
The 'skinny' market may react with displeasure, dropping the pps. The more rational tute investors will then open and add, shaking loose more retail shares.
§
Certainly. The WIPO application for A2-73 in epilepsy is the PCT-preferred method of protection. I surmise MINA of our future IP apps to appear this way. Always ties to Japan pharma(Takata) and I believe in a strong Euro/German connection. Otherwise, we'd be based in California, right?
§
I said +3.5 MMSE and +7 ADCS-ADL at 12 weeks. I'll stick with the numbers but bump it to 18-20 week measure. A positive slope at 20 weeks leaves donepezil in the dust. ≥15% above don/ABIL at 24 weeks with a safe profile and it is new SOC. booya.
§
It was 179,598 initial commitment shares, which is ~$1.32M today. So, yes, it would seem natural to use the deal. However, it has been 8 months since the S3 and it could be that the co felt that outlay worth the security it provides as support/until a collaboration agreement is reached. The LPC deal is subordinate to the straight $100M shelf offering. Until an S3 supplement is filed I would maintain that the prospectus is a backstop measure. The CEO is a professional financier, and this is evidence of his handwork.
I am in agreement that this financing arrangement may be better terms for keeping development in-house and would say that management is more than capable of proceeding in that direction. Missling as stated clearly, though, that late-stage partnership of A2-73 is the goal. I believe this has to do with sacrificing elements of A2-73's development to secure the future of the pipeline and compound(s) which may better provide the 'meat' of the investment.
This company is young. It's key participants are young. I don't believe they are looking for a quick exit, rather skillfully building a platform for a new generation of receptor-based cellular therapies. If you want to see clinical studies with A2-73, wait until it is approved and watch how many combo therapy development agreements we enter into.
Anavex is going to be a divy-hucking monster....IMHO.
Best to all
§
Boy, how do you guys do it? §
No, the aging population and baby boomers.
Wow, it sure is! Helps explain the run-up since then. Likely that number is much smaller now. Glad I have my shares...can just munch popcorn and watch the show
Go traders! ACCUMULATE!!! It's a chance to own one for a change.
§
Not yet, but I'm betting we will fill that slot and Ms Nicole just neglected to add the 'so-far'.
The confusion stems from the difference between shares in accounts which are available to lend to any of the brokerage's customers (standard margin), and shares which the brokerage lends to other firms. The lending agreement covers these broker-broker transactions and is separate from the standard margin account lending agreement. It may be executed on margin, cash or retirement accounts. Whatever % they offer you is less than the % they receive from the borrowing firm.
Without the separate agreement, shares in non-margin accounts are not subject to lending, ever. Neither are shares in a margin account bought on margin (not fully paid for). Shares in certificate form and shares 'on order' can not be borrowed against. Always keep your non-trading shares on order up high, ALWAYS!
I do not advocate the practice. Read the fine print. Your shares can be held hostage and they usually charge a fee if you terminate the agreement before a certain time. 1 year for Fidelity, IIRC.
http://www.finra.org/investors/alerts/stock-based-loan-programs-what-investors-need-know
§
Cannabinoids and SR-1 agonists...living proof:
"I looked upon the body as a laboratory – I used to throw in this chemical and then that one to see what would happen; I was intrigued by that. What one would work against another; I've got a bit of alchemist in me that way. But all experiments must come to an end."
http://www.mensjournal.com/magazine/keith-richards-a-pirate-looks-at-70-20130613
http://www.dailymail.co.uk/tvshowbiz/article-3175516/Rolling-Stones-rocker-Keith-Richards-kicks-day-smoking-joint.html
Patience and perspective
§
How about this. The Sun poster is titled exactly as the original CTAD 2015 abstract, but with the added 'Dose Dependent'. I surmised last year that the CTAD presentation appeared as though some slides were removed, leaving the one (#18 I think) for the only 12 week mark. Sunday's poster may be the full presentation of this 12 week data that they decided not to reveal until further analysis and 26 week results could assure that "there can be no doubt as to the cause-effect relationship of the 12-week efficacy data". That conforms to Occam's Razor.
Wednesday will be a full 26 week readout and AE report concluding that 'Results warrant advancing A2-73 into P2/3'. No 'CURE!'
Missling will present orally at 5:30 on how mixed sigma-1/Mx compounds, when administered in chronic, low-dose combo formulation to early-onset patients may actually halt the progression of the disease. He is far too polite to drop the mic.
Then it's cocktail hour...as usual.
§
The cast is not complete yet.
Writing $12.50s for August...all I needed to know!
I don't play the options, I'm a volatility freak. I did try out this sim:
http://www.cboe.com/tradtool/virtualtrade.aspx
I did not fair too well against the high volatility bio issues I tracked. Blue chip spreads were easier to get a handle on. Learning what to watch for in the chain was more helpful than anything else to me.
Conclusion: Options are for pros and I'm not that pro and don't want to be. I have a life!
Advice: Learn to use short positions to hedge your investments before tackling derivatives.
§
Great posts among a slew of garbage. Peeps don't even know the history of fluticasone, the CEO, the merger, etc. Like shooting fish in a barrel!
GLTA
§
Not over. Opposition to MTD filed yesterday. Welcome back!
https://www.pacermonitor.com/public/case/10241340/Cortina_v_Anavex_Life_Sciences_Corp_et_al
§
Speak for yourself, as you do not have a clue to what "we" are going to do.
I used to think like that too. Then I got tired of losing money.
§
You can always short it yourself. Cover and go long for twice as many shares. "It hurts the first time but then starts to feel real good!"
§
Nice day INNV §
Orveko, what do you make of this one? It is the only Dr V app that I have not listed. It is all molecular composition stuff so I can't tell what exactly it is. Smoking gun?
https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2013008044&recNum=180&docAn=GR2012000030&queryString=(FP/enzyme)%20&maxRec=12958
"The above mentioned compounds present neuroprotective, antiepileptic and antidepressant activity."
§
Maybe get late, they will have to buy? 7.6+
§
Yes, how is that?
No, they must be a controlled company:
"A Controlled Company is a company of which more than 50% of the. voting power for the election of directors is held by an individual, a group or another company"
https://www.sec.gov/rules/sro/nasdaq/2009/34-59424.pdf
This study was NIH funded:
M1 muscarinic receptor activation protects neurons from ß-amyloid toxicity. A role for Wnt signaling pathway
Ginny G. Faríasa, Juan A. Godoya, Félix Hernándezb, Jesús Avilab, Abraham Fisher, Nibaldo C. Inestrosaa,
http://www.sciencedirect.com/science/article/pii/S0969996104001536
Grants are sprinkles on a nice cupcake. We need real funding, Collaboration or $15 X 10MM secondary, to get baking.
Terminator has the oven preheated. The batter awaits one last ingredient...the IP.
§
Publicly held companies must be controlled to receive NIH funding.
"Our company recently just went public, does this affect our ability to apply for SBIR or STTR?
No, public companies are eligible, but they have to ensure they are more than 50 percent directly owned and controlled by one or more individuals (who are citizens or permanent resident aliens of the United States.) When a firm goes public, they must include their shareholders in their ownership determinations."
https://sbir.nih.gov/faqs#investigator15
Can you link to an employment agreement from another CEO which included, as milestones, late-stage developments that require absolute secrecy and non-disclosure beforehand? Such as collaborations, financial arraignments and IP strategies.
That was 2013. Read this board from back then. 123tom and...crickets. Last year's hints were a rare opportunity to capitalize. As the company grows those opportunities get fewer and farther between. High powered analyst/directors taking shares in lieu of cash for fees...HINT-HINT!
§
Ratio of Buy:Sell orders on your L2. A powerful indicator, it is!
Heading into the backwoods...bye-bye cell service...
HAGW
§
The book is 6X6!!! §